These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 7523546)
1. Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases. Stieber P; Dienemann H; Hasholzner U; Fabricius PG; Schambeck C; Weinzierl M; Poley S; Samtleben W; Hofmann K; Meier W Int J Biol Markers; 1994; 9(2):82-8. PubMed ID: 7523546 [TBL] [Abstract][Full Text] [Related]
2. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer. Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359 [TBL] [Abstract][Full Text] [Related]
3. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS. Mady EA Int J Biol Markers; 2001; 16(2):130-5. PubMed ID: 11471896 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the serum markers CEA, NSE, TPS and CYFRA 21.1 in lung cancer. Giovanella L; Ceriani L; Bandera M; Beghe B; Roncari G Int J Biol Markers; 1995; 10(3):156-60. PubMed ID: 8551058 [TBL] [Abstract][Full Text] [Related]
5. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer. Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168 [TBL] [Abstract][Full Text] [Related]
6. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1. van der Gaast A; Schoenmakers CH; Kok TC; Blijenberg BG; Cornillie F; Splinter TA Br J Cancer; 1994 Mar; 69(3):525-8. PubMed ID: 7510117 [TBL] [Abstract][Full Text] [Related]
8. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Pujol JL; Grenier J; Parrat E; Lehmann M; Lafontaine T; Quantin X; Michel FB Am J Respir Crit Care Med; 1996 Sep; 154(3 Pt 1):725-33. PubMed ID: 8810612 [TBL] [Abstract][Full Text] [Related]
10. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383 [TBL] [Abstract][Full Text] [Related]
11. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Rastel D; Ramaioli A; Cornillie F; Thirion B Eur J Cancer; 1994; 30A(5):601-6. PubMed ID: 7521651 [TBL] [Abstract][Full Text] [Related]
12. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: results of a multicenter trial. Bombardieri E; Seregni E; Bogni A; Ardit S; Belloli S; Busetto A; Caniello B; Castelli M; Cianetti A; Correale M Int J Biol Markers; 1994; 9(2):89-95. PubMed ID: 7523547 [TBL] [Abstract][Full Text] [Related]
14. Discriminant analysis on small cell lung cancer and non-small cell lung cancer by means of NSE and CYFRA-21.1. Paone G; De Angelis G; Munno R; Pallotta G; Bigioni D; Saltini C; Bisetti A; Ameglio F Eur Respir J; 1995 Jul; 8(7):1136-40. PubMed ID: 7589398 [TBL] [Abstract][Full Text] [Related]
15. CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels. Molina R; Agusti C; Mañe JM; Filella X; Jo J; Joseph J; Giménez N; Estapé J; Ballesta AM Int J Biol Markers; 1994; 9(2):96-101. PubMed ID: 7523548 [TBL] [Abstract][Full Text] [Related]
16. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Sugama Y; Kitamura S; Kawai T; Ohkubo A; Hasegawa S; Kuriyama T; Kato H; Fukuoka M; Ohkawa J Jpn J Cancer Res; 1994 Nov; 85(11):1178-84. PubMed ID: 7530241 [TBL] [Abstract][Full Text] [Related]
17. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981 [TBL] [Abstract][Full Text] [Related]
18. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742 [TBL] [Abstract][Full Text] [Related]
19. [Basic and clinical studies on serum cytokeratin 19 fragment assay using Centocor CYFRA 21-1 kit in patients with lung cancer]. Hamase A; Sugimoto Y; Maeda M; Kitani H; Fukuchi M Kaku Igaku; 1994 Aug; 31(8):969-76. PubMed ID: 7523748 [TBL] [Abstract][Full Text] [Related]
20. CYFRA 21-1. A new marker in lung cancer. Stieber P; Hasholzner U; Bodenmüller H; Nagel D; Sunder-Plassmann L; Dienemann H; Meier W; Fateh-Moghadam A Cancer; 1993 Aug; 72(3):707-13. PubMed ID: 7687515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]